Effects Of DP-b99 On Neurological Function In Subjects With Acute Ischemic Hemispheric Stroke

NCT00190047 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2007-11-26

No results posted yet for this study

Summary

This study will examine if DP-b99 can improve neurological function (for example strength and coordination) in the 3 months after an acute stroke

Conditions

  • Brain Ischemia
  • Stroke
  • Cerebrovascular Disorders

Interventions

DRUG

DP-b99

Sponsors & Collaborators

  • D-Pharm Ltd.

    lead INDUSTRY

Principal Investigators

  • Gilad Rosenberg, M.D. · D-Pharm Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Completion
2006-10-31

Countries

  • Germany
  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00190047 on ClinicalTrials.gov